TLIPvsESP: Comparing Thoracolumbar Interfascial Plane Block With Erector Spinae Plane Block

Sponsor
Karaman Training and Research Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05023850
Collaborator
(none)
60
1
2
8.4
7.2

Study Details

Study Description

Brief Summary

Major spinal surgery causes greater pain in the postoperative 24 hours. Patients with severe pain may have prolonged hospital stays and delay in mobilization. In addition, chronic pain may be seen in these patients due to ineffectively managed acute postoperative pain. Therefore, optimizing acute postoperative analgesia is a priority in patients undergoing major spinal surgery.

Recently, ultrasound-guided interfascial plane blocks such as thoracolumbar interfascial plane block (TLIPB)and the erector spinae plane block (ESPB) have been described in spinal surgery. Both blocks clinically seem to be safe and easily performed. The aims of this study are to compare the quality of recovery scores, overall morbidity and postoperative analgesia after major spinal surgery in patients receiving either TLIPB or ESPB.

Condition or Disease Intervention/Treatment Phase
  • Procedure: TLIPB
  • Procedure: ESPB
N/A

Detailed Description

Thoracolumbar interfascial plane block (TLIPB)and erector spinae plane block (ESPB) and have been shown to provide effective analgesia after spinal surgery. ESPB targets ventral and dorsal rami of the spinal nerve and also spreads over the paravertebral and epidural space. However, TLIPB targets only dorsal rami of the spinal nerve and spare ventral rami which may provide early ambulation. In addition, depositing local anesthetic in the fascial planes may prevent intraoperative washout. It may translate to an increase in the quality of analgesia. On the other hand, pain is an incomplete measure of postoperative recovery. No study to date has compared these two blocks in terms of the quality of recovery after major spinal surgery. This study will test the hypothesis that patients receiving TLIPB have higher QoR-40 scores in comparison with patients receiving ESPB.

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized control trial one group receives Thoracolumbar Interfascial Plane Block the other receives Erector Spinae Plane BlockRandomized control trial one group receives Thoracolumbar Interfascial Plane Block the other receives Erector Spinae Plane Block
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Blocks will be administered after induction of General Anesthesia so participants will be blinded to which intervention they have had. Study investigators will not be aware of what group the participant belongs to when assessing the patient's post-operative period
Primary Purpose:
Treatment
Official Title:
Comparing Thoracolumbar Interfascial Plane Block With Erector Spinae Plane Block for Thoracolumbar Decompressive Surgery: a Randomized Clinical Trial
Actual Study Start Date :
Sep 10, 2021
Actual Primary Completion Date :
May 23, 2022
Actual Study Completion Date :
May 23, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Group TLIP

Patients will receive a Thoracolumbar Plane Block (TLIPB) under ultrasound guidance while under general anesthesia. Intervention: Patients will receive a TLIPB with 20mls 0.25% Bupivicaine bilaterally.

Procedure: TLIPB
Patients will receive TLIPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
Other Names:
  • Global Quality of Recovery-40 score
  • Standard Pain Follow up and Monitorization
  • Experimental: Group ESP

    Patients will receive an Erector Spinae Plane Block (ESPB) under ultrasound guidance while under general anesthesia. Intervention: Procedure: Patients will receive an ESPB with 20 ml 0.25% Bupivacaine bilaterally.

    Procedure: ESPB
    Patients will receive ESPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between erector spinae muscle and transverse process of a vertebra.
    Other Names:
  • Global Quality of Recovery-40 score
  • Standard Pain Followup and Monitorization
  • Outcome Measures

    Primary Outcome Measures

    1. Quality of Recovery (QoR-40) Score [Postoperative 24th hour]

      QoR-40, a 40-item questionnaire that provides a global score and subscores across five dimensions: patient support, comfort, emotions, physical independence, and pain. I rate each item on a scale of 1-5, providing a minimum score of 40 and maximum of 200.QoR-40, a 40-item questionnaire that provides a global score and sub-scores across five dimensions: patient support, comfort, emotions, physical independence, and pain. Each item is rated on a scale of 1-5, providing a minimum score of 40 and maximum of 200.Global QoR-40 scores range from 40 to 200 representing, respectively, very poor to outstanding quality of recovery. QoR-40 score will be recorded on the morning of operation and at the postoperative 24th hour.

    Secondary Outcome Measures

    1. Area under the Numeric Rating Scale pain score versus time [Postoperative 24 hours]

      11-point Numerical Rating Scale pain score is measured from '0' (means no pain) to '10' (means worst pain imaginable) both at rest and during sitting.

    2. Numeric Rating Scale pain score [Postoperative 24 hours]

      Pain scores using a Numeric Rating Scale (NRS) ranging from 0 to 10 (0= no pain; 10= worst imaginable pain). These scores will be recorded before surgery, in PACU and 6th, 12th and 24th at the postoperative period, both at rest and during sitting. and 24th hour pain imaginable).

    3. Documentation of adverse events [Postoperative 24 hours]

      Nausea and vomiting

    4. Postoperative opioid consumption in the first 24 hours [Postoperative 24 hours]

      Subjects will be extubated, taken to the postanesthesia care unit (PACU) and will be received by a nurse blinded to randomization. A standard PACU opioid algorithm will be used which involved: intravenous fentanyl 25 µg for Numeric Rating Scale (NRS) pain scores of either 4 or 5 intravenous fentanyl 50 µg for NRS of 6 or greater. On discharge to the ward, subjects will be provided immediate-release oral oxycodone 5 mg every 4 hours as needed for NRS of 4-6; and 10 mg every 4 hours as needed for NRS of 7-10. All opioid doses will be converted to morphine equivalents.

    5. Time for administration of first opioid analgesia [Postoperative 24 hours]

      Time to administration of first opioid analgesia in the postanesthesia care unit

    6. Postoperative complications [Postoperative thirty days]

      Postoperative complications will be identified by visiting patients every day or alternate day during their in-hospital course, supplemented by patients' medical records review by assessors masked to group allocation, using our hospital's electronic patient record database. We will use the Claviene Dindo Classification system from which CCI is derived. We defined a postoperative complication as any deviation from the ideal postoperative course, not inherent in the procedure itself and does not constitute a failure to cure. CCI scores will be calculated using the online CCI calculator.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    -≥ 18 years old,

    • Undergoing posterior lumbar spinal one to three levels fusion surgery

    • Having signed a written informed consent form,

    • ASAI-III

    Exclusion Criteria:
    • Contraindication for regional anesthesia (allergy to local anesthetics, neuropathic disease, infection at the puncture site, coagulation disorder, refusal of the technique,…)

    • Contraindication to nonsteroidal anti-inflammatory drugs,

    • Patient who has already had a spinal surgery,

    • Patient with chronic pain syndrome (use > 3 months of morphine, opioid analgesics of class 3, pregabalin or gabapentin) or fibromyalgia,

    • A mental or linguistic inability to understand the study,

    • Pregnant or or breastfeeding women,

    • Patient who can not communicate in Turkish

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Karaman Training and Research Hospital Karaman Turkey 70200

    Sponsors and Collaborators

    • Karaman Training and Research Hospital

    Investigators

    • Study Director: Betul Basaran, MD, DESA, Karaman Training and Research Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Karaman Training and Research Hospital
    ClinicalTrials.gov Identifier:
    NCT05023850
    Other Study ID Numbers:
    • 05-2021/13
    First Posted:
    Aug 27, 2021
    Last Update Posted:
    May 24, 2022
    Last Verified:
    Sep 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Karaman Training and Research Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 24, 2022